aleniglipron vs Semaglutide (Wegovy tablets)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
aleniglipron
Developed by Structure Therapeutics
NCT06703021 · Phase 2 · completed
The study was randomized, triple-blind, and placebo-controlled, with 85 participants. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Registered primary outcomes are safety measures; the weight-loss figures are the trial's prespecified efficacy readout, reported in the sponsor's topline press release and not yet peer reviewed. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: September 2028 · NCT07654361 (registry estimate)
Reported efficacy
Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) (Baseline and week 44); Adverse events of special interest (Baseline and week 44); Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters, including hematology, plasma chemistry, coagulation, and urinalysis (Baseline and week 44); Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters: Common ECG-related variables will be assessed, including but not limited to : heart rate and QRS duration (Baseline and week 44); Number of Participants With Clinically Significant Change From Baseline in Vital Signs, including systolic and diastolic Blood Pressure, Heart Rate, Respiratory Rate, and temperature (Baseline and week 44): Placebo-adjusted mean weight loss 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks (both p<0.0001) (not_applicable)
Result source: NCT06703021
Semaglutide (Wegovy tablets)
Marketed by Novo Nordisk
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT07225816 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | aleniglipron | Semaglutide (Wegovy tablets) |
|---|---|---|
| Body weight, % change | —Trial running · NCT07654361 | -14.9% vs -1.5%−13.4 vs placeboNCT051320882 other results
|
| Weight loss of 5% or more | —Trial running · NCT07654361 | —Not posted · NCT05890976 |
| Weight loss of 10% or more | —Trial running · NCT07654361 | —Not posted · NCT05890976 |
| Waist circumference, change (cm) | —Trial running · NCT07654361 | -11.2 vs -1.4−9.8 vs placeboNCT051320882 other results
|
Body weight, % change
- aleniglipron
- —Trial running · NCT07654361
- Semaglutide (Wegovy tablets)
- -14.9% vs -1.5%−13.4 vs placeboNCT05132088
2 other results
- -15.8% vs -2.2% NCT05035095
- -14.4% vs -2.5% NCT05564117
Weight loss of 5% or more
- aleniglipron
- —Trial running · NCT07654361
- Semaglutide (Wegovy tablets)
- —Not posted · NCT05890976
Weight loss of 10% or more
- aleniglipron
- —Trial running · NCT07654361
- Semaglutide (Wegovy tablets)
- —Not posted · NCT05890976
Waist circumference, change (cm)
- aleniglipron
- —Trial running · NCT07654361
- Semaglutide (Wegovy tablets)
- -11.2 vs -1.4−9.8 vs placeboNCT05132088
2 other results
- -13.4 vs -2.8 NCT05035095
- -12.9 vs -3.1 NCT05564117
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. aleniglipron: 0 of 4 rows · Semaglutide (Wegovy tablets): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Semaglutide (Wegovy tablets) |
|---|---|
| Dropout rate | 4.4%25 mg once dailya NCT05564117 · Phase 3 · registry result, not featured evidence show 2 more results3%50 mg NCT05132088 · Phase 3 · registry result, not featured evidence 4.2%50 mg once daily NCT05035095 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —25 mg once dailya NCT05564117 · Phase 3 · registry result, not featured evidence show 2 more results—50 mg NCT05132088 · Phase 3 · registry result, not featured evidence —50 mg once daily NCT05035095 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 3.9%25 mg once dailya NCT05564117 · Phase 3 · registry result, not featured evidence show 2 more results6%50 mg NCT05132088 · Phase 3 · registry result, not featured evidence 9.6%50 mg once daily NCT05035095 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 25 mg once dailya nausea 46.6% (placebo 18.6%) vomiting 30.9% (placebo 5.9%) nasopharyngitis 21.1% (placebo 26.5%) NCT05564117 · Phase 3 · registry result, not featured evidence show 2 more results50 mg covid-19 30.6% (placebo 33.3%) nausea 25.4% (placebo 7.6%) constipation 20.9% (placebo 9.1%) NCT05132088 · Phase 3 · registry result, not featured evidence 50 mg once daily nausea 51.8% (placebo 15.3%) covid-19 35.6% (placebo 34.5%) constipation 27.5% (placebo 15%) NCT05035095 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Semaglutide (Wegovy tablets)
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 1 more result
show 1 more result
show 2 more results
show 2 more results
show 2 more results
show 2 more results
+ 16 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: aleniglipron's landscape · Semaglutide (Wegovy tablets)'s landscape